bluebird bio: Several Delays Hit By COVID-19 [Seeking Alpha]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Seeking Alpha
SummaryIn my last article, I discussed how bluebird was transitioning into a commercial company with its progress in its clinical programs.Since then, due to the COVID-19 pandemic, several of its programs have been delayed, and its share price has dropped by almost half.While I remain bullish long term, I see no short-term positive catalyst for a sharp recovery.IntroductionSince my last article on bluebird bio (NASDAQ:BLUEannouncedsharedBMYFurther Delays in Zynteglobluebird's lead program is an autologous gene therapy, Zynteglo for the treatment of TDT. TDT is the most severe type of ß-thalassemia and is characterized by severe anemia and lifelong dependence on red blood cell ("RBC") transfusions, which can lead to iron overload, which can be toxic and may lead to progressive multi-organ damage. The effective management of iron overload requires lifelong iron chelation therapy. The only potentially curative therapy for ß-thalassemia has been allogeneic Hematopoietic Stem Cell Transpla
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson (NYSE:JNJ) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (JNJ): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
- Intraocular Lens Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/1/25 - Form 4
- 11/13/25 - Form 13F-HR
- 10/22/25 - Form 10-Q
- JNJ's page on the SEC website